Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epithelial cancer cells co-opt the death ligand TRAIL to avert extrinsic apoptosis while acquiring killing capacity.

Cell death and differentiation·2026
Same author

Chemically-induced degradation of the endoplasmic-reticulum stress sensor IRE1 by a VHL-recruiting chimera.

Nature communications·2025
Same author

Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells.

PLoS biology·2025
Same author

A nonenzymatic dependency on inositol-requiring enzyme 1 controls cancer cell cycle progression and tumor growth.

PLoS biology·2025
Same author

Homeostasis control in health and disease by the unfolded protein response.

Nature reviews. Molecular cell biology·2024
Same author

ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway.

Cancer research communications·2024

Related Experiment Video

Updated: Jun 13, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Botulinum toxin type a for chronic migraine.

Avi Ashkenazi1

  • 1The Neurologic Group of Bucks/Montgomery County, 800 West State Street, Suite 101, Doylestown, PA 18901, USA. aashkenazi2001@yahoo.com

Current Neurology and Neuroscience Reports
|April 29, 2010
PubMed
Summary

Botulinum neurotoxin (BoNT) shows promise for chronic migraine (CM) prevention. Recent studies indicate BoNT is effective for some CM patients, offering a new treatment option beyond oral medications.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Chronic migraine (CM) is a leading cause of daily headaches, often poorly managed by oral preventive drugs.
  • Botulinum neurotoxin (BoNT) is recognized for treating muscle tone disorders and shows emerging evidence of analgesic properties.

Purpose of the Study:

  • To review the scientific data on the analgesic effects of BoNT.
  • To summarize clinical evidence on the efficacy of BoNT for preventing chronic migraine.

Main Methods:

  • Review of scientific literature on BoNT's analgesic properties.
  • Analysis of clinical trial data, including recent studies with strict inclusion criteria, on BoNT for CM treatment.

Main Results:

  • Older clinical trials on BoNT for CM were inconclusive.

More Related Videos

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies
05:49

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Related Experiment Videos

Last Updated: Jun 13, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies
05:49

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

  • Recent, rigorously designed trials demonstrate positive efficacy of BoNT in specific CM patient populations.

    • Conclusions:

    • BoNT possesses analgesic properties relevant to migraine prevention.
    • Evidence supports the use of BoNT as a preventive treatment for certain individuals with chronic migraine.